Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-02-01
2011-02-01
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S134100, C424S192100, C424S275100, C530S350000
Reexamination Certificate
active
07879334
ABSTRACT:
The invention concerns bifunctional fusion molecules for the treatment of IgE-mediated allergic conditions and FcεRI-mediated autoimmune conditions. The invention provides a new therapeutic approach for the treatment of both acute and late-phase allergic responses due to ingestion, inhalation, cutaneous and parenteral exposure to allergens, responses including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as anaphylactic reactions due to exposures such as bee stings or penicillin allergy. In addition, the invention provides for a novel, safer and more efficacious form of allergy vaccination.
REFERENCES:
patent: 4902495 (1990-02-01), Kaliner et al.
patent: 5017693 (1991-05-01), Hylarides et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5141648 (1992-08-01), Hylarides et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5358710 (1994-10-01), Sehon et al.
patent: 5420247 (1995-05-01), Gearing et al.
patent: 5512283 (1996-04-01), Byers et al.
patent: 5558869 (1996-09-01), Burks, Jr. et al.
patent: 5560915 (1996-10-01), Patterson et al.
patent: 5563250 (1996-10-01), Hylarides et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5637454 (1997-06-01), Harley
patent: 5645820 (1997-07-01), Hafler et al.
patent: 5672683 (1997-09-01), Friden et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5736507 (1998-04-01), Boots et al.
patent: 5811265 (1998-09-01), Quertermous et al.
patent: 5817308 (1998-10-01), Scott et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5843449 (1998-12-01), Boots et al.
patent: 5858980 (1999-01-01), Weiner
patent: 5869093 (1999-02-01), Weiner et al.
patent: 5880103 (1999-03-01), Urban et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 5945294 (1999-08-01), Frank et al.
patent: 5965605 (1999-10-01), Cheng et al.
patent: 5973121 (1999-10-01), Burks et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 6043345 (2000-03-01), Saxon et al.
patent: 6093699 (2000-07-01), Sehon et al.
patent: 6103697 (2000-08-01), Bergstrand et al.
patent: 6214974 (2001-04-01), Rosenblum et al.
patent: 6228373 (2001-05-01), Bergstrand et al.
patent: 6228374 (2001-05-01), Bergstrand et al.
patent: 6287792 (2001-09-01), Pardridge et al.
patent: 6372250 (2002-04-01), Pardridge et al.
patent: 7101581 (2006-09-01), Ehrman
patent: 7265208 (2007-09-01), Saxon et al.
patent: 7488804 (2009-02-01), Saxon et al.
patent: 7534440 (2009-05-01), Saxon
patent: 2001/0053770 (2001-12-01), Thomas et al.
patent: 2003/0049237 (2003-03-01), Bannon et al.
patent: 2003/0077282 (2003-04-01), Bigler et al.
patent: 2004/0198961 (2004-10-01), An et al.
patent: 2005/0250934 (2005-11-01), Wang et al.
patent: 2006/0171942 (2006-08-01), Saxon et al.
patent: 2009/0136493 (2009-05-01), Saxon et al.
patent: 2009/0317389 (2009-12-01), Saxon
patent: WO 88/09344 (1988-12-01), None
patent: WO 95/14779 (1995-06-01), None
patent: WO 95/26365 (1995-10-01), None
patent: WO 96/26961 (1996-02-01), None
patent: WO 96/12740 (1996-05-01), None
patent: WO 96/16086 (1996-05-01), None
patent: WO 96/22024 (1996-07-01), None
patent: WO 96/26961 (1996-09-01), None
patent: WO 96/40789 (1996-12-01), None
patent: WO 99/02709 (1999-01-01), None
patent: WO 99/02710 (1999-01-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO 99/57241 (1999-11-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/05254 (2000-02-01), None
patent: WO 02/102320 (2002-12-01), None
patent: WO 02/102320 (2002-12-01), None
Fasler et al., J. Allergy and Clinical Immunology 101(4 pt 1): 521-30, Apr. 1998.
Burks et al, Eur. J Biochem 245: 334-339; 1997.
Stanley et al, Archives of Biochemistry and Biophysics 342(2): 244-253; 1997.
Daeron et al, J Clin Invest 95(2): 577-85, Feb. 1995.
Rafnar et al, J Biol Chem 266(2): 1229-1236, 1991.
Terada et al, Clinical Immunology 120(1): 45-56, 2006.
Tangley et al, A therapy for cat allergies, Thanks to mice, the New York time, pp. 1-2, Apr. 5, 2005.
Saxon et al, J Allergy Clin Immunol 121: 320-325, 2008.
Zhang et al, Immunol Allergy Clin North Am 27(1): 93-103, Feb. 2007.
Zhu et al, Nat Med 11(4): 446-449, Epub Mar. 27, 2005.
Krauss et al., Eur. J. Immunol., 25(1): pp. 192-199 (1995).
Basu et al., The Journal of Biological Chemistry, 268(18): pp. 13118-13127 (1993).
New Riverside University Dictionary, Boston, MA, pp. 933 (1994).
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495 (1994).
Skolnick et al., Trends in Biotech., 18(1): pp. 34-39 (2000).
Tao et al., The Journal of Immunology, 143(8): pp. 2595-2601 (1989).
Zhu et al., Nature Medicine, 1219: pp. 1-4 (2005).
Allen, L., et al., “Modifications to an Fcγ-Fcε Fusion Protein Alter Its Effectiveness in the Inhibition of FcεRI-Mediated Functions,” J. Allergy Clin. Immunol., 120: 462-468, 2007.
Terada, T., et al., “A Chimeric Human-Cat Fcγ-Fel d1 Fusion Protein Inhibits Systemic, Pulmonary, and Cutaneous Allergic Reactivity to Intratracheal Challenge in Mice Sensitized to Fel D1, the Major Cat Allergen,” Clinical Immunology, 4C: 1-12, 2006.
Zhang, Ke, et al., “Chimeric Human Fcγ-Allergen Fusion Proteins in the Prevention of Allergy,” Immunol. Allergy Clin. N. Am., 27: 93-103, 2007.
Zhu, D. et al., “A Chimeric Human-Cat Fusion Protein Blocks Cat-Induced Allergy,” Nature Medicine, pp. 1-4, 2005.
“alphaβ-Crystallin in Multiple Sclerosis”, J. Immunol, vol. 129-135, pp. 1-5, Jul. 20, 2001 (http://www.aIbany.net/˜tjc/crystalline.html).
“Autoantigen Sequences”, pp. 1-3, Jul. 11, 2001 (http://129.206.51.31/mb/ana—base.html).
“Autoimmune Disease: Rapid Progress in our Understanding of Immune Function Promises More Effective Treatments for Autoimmune Disorders”, Nature Biotechnology, vol. 18, pp. IT7-IT9, Supplement 2000.
“Histones and Subclasses”, Jul. 30, 2001, PurifiedAntigens for Autoimmune Testing, (http://www.immunovision.com/pg0019.htm).
Abdelilah, S.G., et al., “Molecular Characterization of the Low-Affinity IgE Receptor Fc EpsilonRII/CD23 Expressed by Human Eosinophils”, Int Immunol, Apr. 1998; 10(4):395-404.
Abramson, M.J., et al., “Allergen immunotherapy for asthma”, The Cochrane Library, Jan. 1998; 1:1-32.
Adamczewski, M., and Kinet, J.P., “The High-Affinity Receptor for Immunoglobulin E” Chemical Immun., 59:173190(1994).
Akdis, C., et al., Epitope-Specific T Cell Tolerance to Phospholipase A2in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 In Vitro, The American Society for Clinical Investigations, Inc., vol. 98(7), pp. 1676-1683,1996.
Alvarez-Fernandez, Marcia, et al., “Inhibition of Mammalian Legumain by Some Cystatins is Due to a Novel Second Reactive Site”, The Journal of Biological Chemistry, vol. 274, No. 27, Issue of Jul. 2, pp. 19195-19203, 1999.
American Autoimmune Related Diseases Association, Questions and Answers, pp. 1-4, Jul. 26, 2001 (http://www.aarda.org/questions—and—answers.html).
Ansari, AA, et al., “Epitope Mapping of the Branched Chain Alpha-Ketoacid Dehydrogenase Dihydrolipoyl Transacylase (BCKD-E2) Protein that Reacts with Sera from Patients with Idiopathic Dilated Cardiomyopathy”, (abstract), J Immunol, 153(10):4754-65, Nov. 15, 1994.
Antoniou, A. N., et al., “Control of Antigen Presentation by a Single Protease Cleavage Site”, Immunity, vol. 12, pp. 391-398, Apr. 2000.
Arm et al., “Molecular Cloning of gp49, a Cell-surface Antigen That is Preferentially Expressed by Mouse Mast Cell Progenitors and is a New Member of the Immunoglobulin Superfamily” J. Biol. Chem. 266:15966-73 (1991).
Arm, J.P., et al., “Molecular Identification of a Novel Family of Human Ig Superfamily Members That Possess Immunoreceptor Tyrosine-Based Inhibition Motifs and Homology to the Mouse gp49B1 Inhibitory Receptor1, 2”, J. Immunol.,
Saxon Andrew
Zhang Ke
Zhu Daocheng
Arnold & Porter LLP
Dreger Ginger R.
Fox James A.
Huynh Phuong
The Regents of the University of California
LandOfFree
Fusion molecules and treatment of IgE-mediated allergic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion molecules and treatment of IgE-mediated allergic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion molecules and treatment of IgE-mediated allergic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640288